Innovation amidst post-socialist reform: Jonas Salk and the birth of the Sabin strains-derived inactivated polio vaccine in China.

Abstract

As an industrial science, vaccinology is susceptible to changing social, economic and political frameworks. This article reconstructs the history of the birth of the Sabin strains-derived inactivated polio vaccine (sIPV) in China. The development of this nascent vaccine can be attributed first and foremost to the circulation of knowledge and technology in the global polio research network of the 1980s, before the privatization of vaccine manufacturing and the escalation of intellectual-property protections. Tracing correspondence between Jonas Salk and a Chinese scientist, Jiang Shude, and his colleagues, we chart how institutional efforts in search of a profitable product and scientists' motives in pursuing personal careers in the post-socialist reform era led to collaboration on many levels, centered around polio vaccines. In response to recent polio history research, we also emphasize the impact of multiple temporalities of polio dramaturgy on the vaccine manufacturer, as this article demonstrates how the confluence of shifting global polio eradication agendas and contingencies in complex vaccinology undertakings ironically helped to materialize the idea of the sIPV. Finally, stories of vaccines and scientists in China add compelling subplots to the global polio history, which reveals the need to reconsider the politicization of imported technology in broader socialist contexts.A letter dated '3 June 1986' was mailed from Jonas Salk to Jiang Shude (). Jiang had been an unknown vaccinologist working at the Institute of Medical Biology (IMB) in Flower Red Cave in the Western Hills of Kunming, in south-western China. Salk had visited two years earlier to discuss the feasibility of the IMB's proposal to manufacture inactivated polio vaccine (IPV). The initial collaborative plan had come to a halt by the time Salk wrote the letter to Jiang; still, he kindly offered Jiang an opportunity to travel to Bilthoven and then Lyon to learn IPV-related technology with a generous $10,000 grant for his one-year stay in Europe.